'If you want big pharma exposure, with fewer headaches related to U.S. politics, you could always buy a well-run foreign drug company,' CNBC's Jim Cramer says.
"If you want big pharma exposure, with fewer headaches related to U.S. politics, you could always buy a well-run foreign drug company," he said, because they are not so dependent on the American market.of the improving presidential prospects of Sen. Elizabeth Warren, D-Mass. They trimmed their holdings in the sector over Warren's uncertain chances of getting lawmakers to pass a national health-care policy that would upend the U.S. health-care system.
The drugmaker also has a number of cancer-fighting products in the pipeline that can contribute to its growth. "I'm even more bullish about GlaxoSmithKline than I was in January," Cramer said. "With the stock selling for less than 14 times earnings, I'm calling it a steal. Plus, [CEO Emma] Walmsley's paying you to wait: 4.8% yield. That's a good investment."
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Jim Cramer: How Nike keeps delivering results, despite China trade headwindsInstead of being beholden to the trade war, 'Nike's actually the most in control of its own destiny,' Jim Cramer says.
Consulte Mais informação »
Apeel Sciences CEO tells Jim Cramer how they save your fruit while saving grocery stores money'We use food to preserve food,' says Apeel Sciences CEO James Rogers, whose company has partnered with Kroger to sell avocados that age at a slower rate.
Consulte Mais informação »
Wall Street is 'terrified' of Elizabeth Warren — Jim Cramer says buy dips in health-care stocks'I think it's too soon to count out UNH. It's too soon to write off Cigna. These companies are coining money,' Jim Cramer says.
Consulte Mais informação »
Jim Cramer breaks down Peloton's IPO, reveals the right time to buy the stockExercise equipment manufacturer Peloton debuted on the Nasdaq Composite at $27 per share. Jim Cramer recommends starting a position at least $4 below the open price.
Consulte Mais informação »
'This is how people get hurt' — Cramer warns against getting too excited about Peloton's IPO“This is the kind of thing that will be exciting for today, tomorrow. And then, I think we’re going to look back and say, ‘What were we thinking,’” MadMoneyOnCNBC's Jim Cramer says about Peloton's IPO.
Consulte Mais informação »
Cramer on Peloton: 'I don't want your desperate deal'Peloton went public on the Nasdaq yesterday. Here’s why MadMoneyOnCNBC's JimCramer thinks “Peloton was the wrong place, wrong time.”
Consulte Mais informação »